Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | TAS2R38 | P59533 | 3/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL1286893 | 0.98 | HSD17B10 (0.46) | HSD17B10TAS2R38NAPRTPHGDHTP53 | |
| Hydrochloric Acid SCHEMBL9425234 | 0.98 | HSD17B10 (0.46) | HSD17B10TAS2R38NAPRTPHGDHTP53 | |
| Iodide SCHEMBL11163470 | 0.81 | HPGD (0.56) | ALDH1A1SMN1; SMN2EPHX1KMT2AMEN1 | |
| SCHEMBL11674215 | 0.80 | SMN1; SMN2 (0.57) | HSD17B10NAPRTTP53TSHRSMN1; SMN2 | |
| SCHEMBL14949473 | 0.80 | HSD17B10 (0.55) | HSD17B10ALDH1A1SMN1; SMN2CYP3A4KMT2A | |
| Iodide SCHEMBL11158017 | 0.80 | MITF (0.51) | ALDH1A1SMN1; SMN2EPHX2KMT2AMEN1 | |
| SCHEMBL14949457 | 0.79 | MAPT (0.50) | HSD17B10TP53ALDH1A1TSHREPHX1 | |
| SCHEMBL1387773 | 0.79 | ALDH1A1 (0.46) | HSD17B10TAS2R38NAPRTPHGDHALDH1A1 | |
| SCHEMBL6225141 | 0.78 | HPSE (0.55) | TP53ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30073943 | 0.78 | HPSE (0.55) | TP53ALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024175081-A1 | SHP2 INHIBITOR COMPOUND AND USE THEREOF | 深圳真实生物医药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| US-11351164-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220009884-A1 | MITOCHONDRIAL ACTIVITY INHIBITORS TARGETING TUMORAL METABOLISM | UNIVERSITE GRENOBLE ALPES (FR) | 2022-01-13 | — | — | US | disclosed |
| US-20210283123-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-16 | — | — | US | disclosed |
| WO-2020109506-A1 | MITOCHONDRIAL ACTIVITY INHIBITORS TARGETING TUMORAL METABOLISM | CENTRE LEON BERARD (FR) | 2020-06-04 | — | — | WO | disclosed |
| EP-3503916-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | Bristol-Myers Squibb Company (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2019011170-A1 | OXADIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-01-17 | — | — | WO | disclosed |
| EP-2550266-B1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTICS SOLUTIONS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| WO-2018039518-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20170114155-A1 | CHEMICALLY FUNCTIONALIZED RENEWED RUBBER COMPOSITION | LEHIGH TECHNOLOGIES, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| CN-1033624-A | High-potency sweetener | NUTRASWEET CO (US) | 1989-07-05 | — | — | CN | disclosed |
| WO-1989000563-A1 | HIGH POTENCY SWEETENING AGENTS | THE NUTRASWEET COMPANY (US) | 1989-01-26 | — | — | WO | disclosed |
| CN-87102765-A | The preparation method of sweeting agent N-guanidines guanidine-acetic acid and N-phenyl ethanamidine guanidine-acetic acid derivative and the prescription of this class sweeting agent | — | 1987-10-21 | — | — | CN | disclosed |
| US-4475942-A | N-Phosphonomethylglycine derivatives and herbicidal compositions containing them | GESHURI LABORATORIES LTD. (IL) | 1984-10-09 | — | — | US | disclosed |
| EP-0103055-A1 | N-phosphonomethylglycine derivatives and herbicidal compositions containing them | Geshuri Laboratories Ltd. (IL) | 1984-03-21 | — | — | EP | disclosed |
| US-4293690-A | PROTECTING HYDROXYLS OF 5-AMINO-1-B-D-RIBOFURANOSYLIMIDAZOLE-4-CARBOXAMIDE, DEHYDRATION, CYCLIZATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-10-06 | — | — | US | disclosed |
| EP-0017465-A1 | Production of 2,6-diaminonebularines | Takeda Chemical Industries, Ltd. (JP) | 1980-10-15 | — | — | EP | disclosed |
| US-4101675-A | ANTIHYPERTENSIVES | AKZONA INCORPORATED (US) | 1978-07-18 | — | — | US | disclosed |
| US-3972932-A | Novel 2,6-disubstituted phenyl-aminoguanidine compounds | AKZONA INCORPORATED (US) | 1976-08-03 | — | — | US | disclosed |
| US-3944560-A | BRONCHODILATOR | MERCK & CO., INC. (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351164-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | HSD17B10 1223/4885TAS2R38 4813/4885NAPRT 546/4885 |
| US-20220009884-A1 | MITOCHONDRIAL ACTIVITY INHIBITORS TARGETING TUMORAL METABOLISM | NDUFAB1, CYP11B1, ME3 | HSD17B10 177/4885TAS2R38 2638/4885NAPRT 992/4885 |
| US-20210283123-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | HSD17B10 1223/4885TAS2R38 4813/4885NAPRT 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.